Andreas Schröeder
About
Andreas Schröeder is a scholar working on Oncology, Molecular Biology and Immunology.
According to data from OpenAlex, Andreas Schröeder has authored 20 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in Andreas Schröeder's work include Cancer Immunotherapy and Biomarkers (4 papers), Lung Cancer Treatments and Mutations (4 papers) and DNA Repair Mechanisms (3 papers). Andreas Schröeder is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Lung Cancer Treatments and Mutations (4 papers) and DNA Repair Mechanisms (3 papers). Andreas Schröeder collaborates with scholars based in Germany, United States and Italy. Andreas Schröeder's co-authors include Odilo Mueller, Susanne Stocker, Ruediger Salowsky, Wolfram Menzel, Martin Granzow, Marcus Gassmann, Thomas Ragg, Michael J. Leiber, Jean Bourhis and Michael Moran and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Andreas Schröeder
18 papers receiving 2.1k citations
Hit Papers
Peers
Andreas Schröeder
Marcus Gassmann Germany
Bo Zhou China
Sun Shim Choi South Korea
Alejandra Cervera Finland
Ruediger Salowsky Germany
Odilo Mueller United States
Sean C. Taylor United States
Laurent‐Philippe Albou United States
Diane S. Kang United States
Jie Jiang United States
Citations per year, relative to Andreas Schröeder Andreas Schröeder (= 1×)
peers
Marcus Gassmann
Countries citing papers authored by Andreas Schröeder
Since
Specialization
Citations
This map shows the geographic impact of Andreas Schröeder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Schröeder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Schröeder more than expected).
Fields of papers citing papers by Andreas Schröeder
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Andreas Schröeder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Schröeder. The network helps show where Andreas Schröeder may publish in the future.
Co-authorship network of co-authors of Andreas Schröeder
This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Schröeder. A scholar is included among the top collaborators of Andreas Schröeder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Schröeder. Andreas Schröeder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
O’Leary, Ben, Heath D. Skinner, Jonathan D. Schoenfeld, et al.. (2024). Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck. Cancer Treatment Reviews. 129. 102773–102773.
2.
Bourhis, Jean, S. Peter Eggleton, Andreas Schröeder, et al.. (2024). Phase 2 study of xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A post hoc activity analysis by blinded independent review committee evaluation.. Journal of Clinical Oncology. 42(16_suppl). e18039–e18039.
3.
Saba, Nabil F., et al.. (2023). 890P Real-world survival outcomes and survival risk factors in elderly patients with locally advanced squamous cell carcinoma of the head and neck. Annals of Oncology. 34. S570–S570.
4.
Strauss, Julius, Jean‐Laurent Deville, Mario Sznol, et al.. (2023). First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. Journal for ImmunoTherapy of Cancer. 11(5). e005813–e005813.
5.
Vugmeyster, Yulia, Elisabeth Rouits, Paul M. Diderichsen, et al.. (2023). Model‐Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Clinical Pharmacology & Therapeutics. 115(1). 52–61.
6.
Ferris, Robert L., Kevin J. Harrington, Jonathan D. Schoenfeld, et al.. (2022). Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck. Cancer Treatment Reviews. 113. 102492–102492.
7.
Vugmeyster, Yulia, Elisabeth Rouits, Paul M. Diderichsen, et al.. (2022). Abstract 5424: Selection of RP3D of xevinapant in combination with CRT in patients with LA SCCHN. Cancer Research. 82(12_Supplement). 5424–5424.
8.
Andrić, Zoran, Gabriella Gálffy, Manuel Cobo, et al.. (2021). 103P First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 16(4). S753–S754.
9.
Bourhis, Jean, Alexander Stein, Jan Paul de Boer, et al.. (2021). Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. Cancer Treatment Reviews. 97. 102172–102172.
10.
Lakhani, Nehal J., Amita Patnaik, John B. Liao, et al.. (2020). A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.. Journal of Clinical Oncology. 38(5_suppl). 18–18.
11.
Alimzhanov, Marat, Parantu K. Shah, Andreas Schröeder, et al.. (2020). Abstract 964: Induction of immunogenic cell death and interferon signaling by carboplatin and the ATR inhibitor M6620 may contribute to anti-tumor activity of M6620-carboplatin-avelumab triplet combination in MC38 tumor model. Cancer Research. 80(16_Supplement). 964–964.
12.
Alimzhanov, Marat, Patricia Soulard, Astrid Zimmermann, et al.. (2019). Abstract 2269: ATR inhibitor M6620 enhances anti-tumor efficacy of the combination of the anti-PD-L1 antibody avelumab with platinum-based chemotherapy. Immunology. 2269–2269.
13.
Banerjee, Susana, Nicoletta Colombo, Minal Barve, et al.. (2019). Randomized, phase Ib/II study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer. Annals of Oncology. 30. v431–v432.
14.
Alimzhanov, Marat, Patricia Soulard, Astrid Zimmermann, et al.. (2019). Abstract 2269: ATR inhibitor M6620 enhances anti-tumor efficacy of the combination of the anti-PD-L1 antibody avelumab with platinum-based chemotherapy. Cancer Research. 79(13_Supplement). 2269–2269.
15.
Koch, Sven D., Henoch S. Hong, Susan Feyerabend, et al.. (2014). A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive®-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part. Journal for ImmunoTherapy of Cancer. 2(Suppl 3). P85–P85.
16.
Mitchell, Paul, Thomas John, Carmel Murone, et al.. (2013). Mucin 1 (MUC1) expression in patients (pts) with early stage non-small cell lung cancer (NSCLC): Relationship between immunohistochemistry (IHC), tumor characteristics, and survival.. Journal of Clinical Oncology. 31(15_suppl). 3011–3011.
17.
Lü, Ping, Judit Knisz, Andreas Marquardt, et al.. (2010). The Justy mutation identifies Gon4-like as a gene that is essential for B lymphopoiesis. The Journal of Experimental Medicine. 207(7). 1359–1367.
18.
Schröeder, Andreas, Odilo Mueller, Susanne Stocker, et al.. (2006). The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Molecular Biology. 7(1). 3–3.
19.
Köbberling, Johannes, et al.. (2005). Determination of albuminuria in the urine of diabetics for prevention and control of diabetic nephropathy. SHILAP Revista de lepidopterología.
20.
Mueller, Odilo, et al.. (2004). RNA integrity number (RIN) - towards standardization of RNA quality assessment. Cancer Research. 64. 380–380.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Marcus Gassmann Breakdown of academic impact, for papers by Bo Zhou Breakdown of academic impact, for papers by Sun Shim Choi Breakdown of academic impact, for papers by Alejandra Cervera Breakdown of academic impact, for papers by Ruediger Salowsky Breakdown of academic impact, for papers by Odilo Mueller Breakdown of academic impact, for papers by Sean C. Taylor Breakdown of academic impact, for papers by Laurent‐Philippe Albou Breakdown of academic impact, for papers by Diane S. Kang Breakdown of academic impact, for papers by Jie Jiang